Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Inclusion Criteria: * Male or female subjects who are ≥18 years of age； * Histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage IB-III) disease * Clinical stage IIA/IIB/IIIA/IIIB assessed by EBUS-TBNA or PET(positron emission tomography)/CT can be resected. * Documented ALK-fusion positive（ Ventana , assessed by a local laboratory） * ECOG PS 0-1 * Performance status (ECOG) 0-1 at enrolment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing of lorlatinib * Hematology , liver and kidney function are adequate for induction therapy . * Cardiopulmonary function suitable for surgical treatment (ECG, echocardiography, pulmonary function or blood gas analysis). * Be willing and able to provide written informed consent for the trial prior to any study specific procedures. The subject must also provide consent for correlative translational study. * Female participants of childbearing potential must agree to use acceptable methods of contraception * Male patients must be willing to use barrier contraception. Provide written informed consent. Exclusion Criteria: * Mixed squamous cell carcinoma, large cell carcinoma, small cell lung cancer. * Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug. * Pregnant female patients; breastfeeding female patients. * Malignancies other than the disease under study within 3 …